Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Updated safety results of a phase II trial (AGMT MBC-6)

Gabriel Rinnerthaler; Simon Peter Gampenrieder; D Voskova; A Petzer; M Hubalek; E Petru; B Hartmann; J Andel; M Balic; Thomas Melchardt; Brigitte Mlineritsch; Richard Greil

doi:10.1093/annonc/mdw365.18

Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Updated safety results of a phase II trial (AGMT MBC-6)

Gabriel Rinnerthaler
, Simon Peter Gampenrieder
, D Voskova
, A Petzer
, M Hubalek
, E Petru
, B Hartmann
, J Andel
, M Balic
, Thomas Melchardt
, Brigitte Mlineritsch
, Richard Greil

Universitätsklinik für Innere Medizin 3 - Hämatologie, internistische Onkologie, Hämostaseologie, Infektiologie, Rheumatologie und Onkologisches Zentrum

Publikation: Beitrag in Fachzeitschrift › Abstrakt (Zeitschrift) › Begutachtung

Originalsprache	Englisch
Fachzeitschrift	ANNALS OF ONCOLOGY
Jahrgang	27
DOIs	https://doi.org/10.1093/annonc/mdw365.18
Publikationsstatus	Veröffentlicht - 2016

Zugriff auf Dokument

10.1093/annonc/mdw365.18

Dieses zitieren

Rinnerthaler, G., Gampenrieder, S. P., Voskova, D., Petzer, A., Hubalek, M., Petru, E., Hartmann, B., Andel, J., Balic, M., Melchardt, T., Mlineritsch, B., & Greil, R. (2016). Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Updated safety results of a phase II trial (AGMT MBC-6). ANNALS OF ONCOLOGY , 27. https://doi.org/10.1093/annonc/mdw365.18

Rinnerthaler, Gabriel ; Gampenrieder, Simon Peter ; Voskova, D et al. / Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Updated safety results of a phase II trial (AGMT MBC-6). in: ANNALS OF ONCOLOGY 2016 ; Jahrgang 27.

@article{acc359e56c4d4ab0acd600b73aa37f52,

title = "Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Updated safety results of a phase II trial (AGMT MBC-6)",

author = "Gabriel Rinnerthaler and Gampenrieder, \{Simon Peter\} and D Voskova and A Petzer and M Hubalek and E Petru and B Hartmann and J Andel and M Balic and Thomas Melchardt and Brigitte Mlineritsch and Richard Greil",

year = "2016",

doi = "10.1093/annonc/mdw365.18",

language = "English",

volume = "27",

journal = "ANNALS OF ONCOLOGY ",

issn = "0923-7534",

publisher = "Elsevier ",

}

Rinnerthaler, G , Gampenrieder, SP, Voskova, D, Petzer, A, Hubalek, M, Petru, E, Hartmann, B, Andel, J, Balic, M, Melchardt, T, Mlineritsch, B & Greil, R 2016, 'Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Updated safety results of a phase II trial (AGMT MBC-6)', ANNALS OF ONCOLOGY , Jg. 27. https://doi.org/10.1093/annonc/mdw365.18

Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Updated safety results of a phase II trial (AGMT MBC-6). / Rinnerthaler, Gabriel ; Gampenrieder, Simon Peter; Voskova, D et al.
in: ANNALS OF ONCOLOGY , Jahrgang 27, 2016.

Publikation: Beitrag in Fachzeitschrift › Abstrakt (Zeitschrift) › Begutachtung

TY - JOUR

T1 - Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Updated safety results of a phase II trial (AGMT MBC-6)

AU - Rinnerthaler, Gabriel

AU - Gampenrieder, Simon Peter

AU - Voskova, D

AU - Petzer, A

AU - Hubalek, M

AU - Petru, E

AU - Hartmann, B

AU - Andel, J

AU - Balic, M

AU - Melchardt, Thomas

AU - Mlineritsch, Brigitte

AU - Greil, Richard

PY - 2016

Y1 - 2016

U2 - 10.1093/annonc/mdw365.18

DO - 10.1093/annonc/mdw365.18

M3 - Abstract (Journal)

SN - 0923-7534

VL - 27

JO - ANNALS OF ONCOLOGY

JF - ANNALS OF ONCOLOGY

ER -

Rinnerthaler G , Gampenrieder SP, Voskova D, Petzer A, Hubalek M, Petru E et al. Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Updated safety results of a phase II trial (AGMT MBC-6). ANNALS OF ONCOLOGY . 2016;27. doi: 10.1093/annonc/mdw365.18